Get started

Press Releases

Delayed 3m

Fastest customizable press release feed in the world.

Signed out · 3-min delay · Sign up for real-time

Updates arrive automatically.

  • Alamar Biosciences Partners with GSK on Large-Scale Proteomic Study to Advance Precision Medicine
    PR·

    Alamar Biosciences Partners with GSK on Large-Scale Proteomic Study to Advance Precision Medicine

    Alamar Biosciences, Inc. (NASDAQ:ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced a strategic scientific collaboration with GSK plc (LSE/NYSE:GSK) that will use Alamar’s NULISA™ platform in a large-scale study examining how circulating protein signatures relate to disease progression, biological subtypes and treatment response across respiratory, liver, kidney, neurological and autoimmune conditions. The collaboration intends to generate deep proteomic insights to advance precision prevention, treatment and earlier disease detection in real-world health care settings. Many d

    $ALMR$GSK
  • 22nd Century Group to Announce Third Quarter 2026 Results on November 16, 2026
    PR·

    22nd Century Group to Announce Third Quarter 2026 Results on November 16, 2026

    22nd Century Group, Inc. (NASDAQ:XXII), the only low nicotine tobacco company in the world, will host a webcast on Monday, November 16, 2026, at 8:00 AM ET to discuss its 2026 third quarter results, which are to be reported in a press release at approximately 6:00 AM ET the same day. During the webcast, Larry Firestone, chairman and chief executive officer, and Dan Otto, chief financial officer, will review financial results and provide an update on recent commercial, regulatory and operational activities. The live and archived webcast will be accessible on the Events web page in the Company's Investor Relations section of the website,

    $XXII
  • Globus Medical Acquires Synaptive Medical, Strengthening Its Position in Cranial Neurosurgery
    PR·

    Globus Medical Acquires Synaptive Medical, Strengthening Its Position in Cranial Neurosurgery

    Globus Medical, Inc. a leading musculoskeletal technology company, today announced that it completed the acquisition of Synaptive Medical, deepening the Company's presence in cranial neurosurgery and positioning it for further growth in this market. Synaptive Medical is a medical technology company focused on developing solutions for complex cranial procedures, with technologies spanning surgical visualization, navigation, surgical planning, and MRI. The acquisition completed on August 4, 2026, through a court-appointed receivership process, adds to Globus Medical's portfolio of enabling technologies for neurosurgery. "This acquisition buil

    $GMED
  • Aura Biosciences to Participate in Upcoming Investor Conference
    PR·

    Aura Biosciences to Participate in Upcoming Investor Conference

    Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today announced that Natalie Holles, CEO and President, will participate in the following upcoming investor conference: Stifel 2026 Healthcare Conference on Tuesday, November 10, 2026. Fireside chat at 2:40 p.m. ET The live webcast of the fireside chat will be available on the "Investors & Media" page under the "Events & Presentations" section of the Company’s website at https://ir.aurabiosciences.com/events-and-presentations, where a replay of the webcast will be archived f

    $AURA
  • AMGEN REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS
    PR·

    AMGEN REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS

    Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2026."Amgen delivered another strong quarter as our strategy for long-term growth continued to produce results across the enterprise," said Robert A. Bradway, chairman and chief executive officer. "The strength of our commercial portfolio, combined with important clinical advances and a promising late-stage pipeline, reinforces our confidence in Amgen's ability to deliver durable growth well into the next decade."Key results include:For the third quarter, total revenues increased 8% to $10.4 billion in comparison to the third quarter of 2025. Product sales grew 8%

    $AMGN
  • RAMACO RESOURCES REPORTS THIRD QUARTER 2026 RESULTS
    PR·

    RAMACO RESOURCES REPORTS THIRD QUARTER 2026 RESULTS

    Ramaco Resources, Inc. (NASDAQ:METC, METCB, ", Ramaco", or the ", Company", )) is a leading operator and developer of high-quality, low-cost metallurgical coal in Central Appalachia and is exploring a coal, rare earth, and other critical minerals project in Wyoming. Today it reported financial results for the three and nine months ended September 30, 2026 (the "Results"). THIRD QUARTER 2026 HIGHLIGHTSThe Company had a quarterly net loss of $(18.2) million and Class A diluted EPS of $(0.32). The Company had quarterly Adjusted EBITDA of $3.0 million, defined as adjusted earnings before interest, taxes, depreciation, amortization, equity-based compens

    $METC$METCB
  • Red Rock Resorts Announces Third Quarter 2026 Results
    PR·

    Red Rock Resorts Announces Third Quarter 2026 Results

    Red Rock Resorts, Inc. ("Red Rock Resorts," "we" or the "Company") (NASDAQ:RRR) today reported financial results for the third quarter ended September 30, 2026. Third Quarter ResultsConsolidated OperationsNet revenues were $488.7 million for the third quarter of 2026, an increase of 2.8%, or $13.1 million, from $475.6 million in the same period of 2025. Net loss was $17.7 million for the third quarter of 2026, a decrease of 123.0%, or $94.6 million, from net income of $76.9 million in the same period of 2025, primarily as a result of $79.1 million in share-based compensation expense related to the Company's 50th anniversary stock awards issued in Q3 202

    $RRR
  • Skyworks Begins New Chapter Following Qorvo Combination; Reports Fourth Quarter and Fiscal 2026 Results
    PR·

    Skyworks Begins New Chapter Following Qorvo Combination; Reports Fourth Quarter and Fiscal 2026 Results

    Creates a Full-Stack RF Front-End Platform for Next-Generation SmartphonesExpands Reach Across Four Secular Growth Markets – Physical AI, Defense, Infrastructure, and AutomotiveBroadens Technology Portfolio with RF GaN, Low-Voltage Power and Wired BroadbandTargets $500 Million or More of Annual Cost Synergies Skyworks Standalone Revenue of $1.046 Billion, GAAP Diluted EPS of $0.15 and Non-GAAP Diluted EPS of $1.28

    $SWKS
  • Greif Reports Fourth Quarter and Fiscal 2026 Results
    PR·

    Greif Reports Fourth Quarter and Fiscal 2026 Results

    Greif, Inc. (NYSE:GEF, GEF.B)), a world leader in industrial packaging products and services, today announced fourth quarter and fiscal 2026 results. On June 30, 2025, we entered into a definitive agreement to divest our Containerboard Business, including our CorrChoice sheet feeder system. Beginning in the third quarter of fiscal 2025, the Containerboard Business has been reported as discontinued operations. Unless otherwise noted, all financial results and discussions in this press release relate to continuing operations. Additional information regarding the basis of presentation and changes in reportable segments is provided under "Basi

    $GEF$GEF.B
  • Avis Budget Group Reports Third Quarter 2026 Results
    PR·

    Avis Budget Group Reports Third Quarter 2026 Results

    Avis Budget Group, Inc. (NASDAQ:CAR) announced financial results for the third quarter ended September 30, 2026 today. We ended the quarter with revenues of $3.4 billion, net income of $199 million, and an Adjusted EBITDA1 of $513 million. "The third quarter demonstrated continued progress in how we manage our fleet, with third-quarter Americas utilization being the best we have had in twenty years despite a softer travel demand environment," said Brian Choi, Avis Budget Group CEO. "We are building on the improvements we've made in fleet management and field operations with the objective of improving transaction economics, strengthenin

    $CAR
  • Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
    PR·

    Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

    - Q3 2026 net product sales of $185.7 million; 2026 net product sales guidance increased to $715 million to $720 million - Received U.S. FDA approval of and launched ATEBRIOZ® for FOP - Announced three positive readouts setting up planned regulatory submissions for LIVMARLI®, ATEBRIOZ and brelovitug - Received U.S. FDA Orphan Drug Designation for brelovitug in HDV - Conference call to provide business updates today, November 3 at 1:30 p.m. PT / 4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today reported financial results for the third quarter 2026 and provided a business update. "The third quarter was an important period of execution fo

    $MIRM
  • Flywire Reports Third Quarter 2026 Financial Results
    PR·

    Flywire Reports Third Quarter 2026 Financial Results

    Third Quarter Revenue Increased 25.1% Year-over-Year Third Quarter Revenue Less Ancillary Services Increased 26.0% Year-over-Year Previous Fiscal Year 2026 FX-Neutral Revenue Less Ancillary Services growth guidance raised by 2 pts at midpoint, Adjusted EBITDA margin growth guidance raised by 30 bps at midpoint

    $FLYW
  • The Manitowoc Company Reports Strong Third-Quarter 2026 Results; Raises Full Year Guidance
    PR·

    The Manitowoc Company Reports Strong Third-Quarter 2026 Results; Raises Full Year Guidance

    Third-Quarter 2026 Highlights Orders of $676.4 million, up 37.6% year-over-year. Backlog of $1,110.9 million at quarter end Net sales of $613.8 million, up 10.9% year-over-year Net income of $11.0 million, up 120% year-over-year Adjusted EBITDA(1) of $47.4 million, up 39.0% year-over-year The Manitowoc Company, Inc. (NYSE:MTW) (the "Company" or "Manitowoc") today reported third-quarter net income of $11.0 million, or $0.30 per diluted share. Third-quarter adjusted net income(1) was $11.5 million or $0.31 per diluted share. Orders in the third quarter were $676.4 million, a 37.6% increase from the prior year, resulting in backlog of $1,110.9 million at the end of the qua

    $MTW
  • ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
    PR·

    ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

    ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today announced that management will be participating in the following investor conferences in November: Guggenheim’s 3rd Annual Healthcare Innovation Conference – Participating in a fireside chat on Tuesday, November 10, 2026, at 10:30 a.m. ET. Management will also be participating in one-on-one meetings. Stifel 2026 Healthcare Conference – Participating in a fireside chat on Wednesday, November 11, 2026, at 2:00 p.m. ET. Management wil

    $ORIC
  • Key Tronic Corporation Announces Results for the First Quarter of Fiscal 2027
    PR·

    Key Tronic Corporation Announces Results for the First Quarter of Fiscal 2027

    Key Tronic Corporation (NASDAQ:KTCC), a provider of electronic manufacturing services (EMS), today announced its results for the quarter ended September 26, 2026. For the first quarter of fiscal year 2027, Key Tronic reported total revenue of $98.7 million, compared to $98.8 million in the same period of fiscal year 2026. Revenue for the first quarter of fiscal year 2027 continued to be constrained by tightening credit availability and liquidity pressures across the global supply chain. These supply chain financing constraints delayed approximately $18 million of the Company's shipments during the quarter, mostly involving programs

    $KTCC
  • Denali Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
    PR·

    Denali Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights

    AVLAYAH® (tividenofusp alfa-eknm) net product revenue accelerated to $17.8 million in its second full commercial quarterContinued growth expectations drive Q4 2026 net product revenue guidance of $30.0 million to $32.0 millionAVLAYAH recognized as the "Best Biotechnology Product" of 2026 by The Galien FoundationZafinofusp alfa advancing as Denali’s second potential product, with BLA submission on track for 2027 seeking accelerated approval for Sanfilippo syndrome type A (MPS IIIA)Five TransportVehicle™ (TV) programs expected to generate data in 2027: zafinofusp alfa (ETV:SGSH), DNL593 (PTV:PGRN), DNL628 (OTV:MAPT), DNL921 (ATV:Abeta) and DNL952 (ETV:GAA)Q3 2026 net income of $70.1 million in

    $DNLI
  • United Fire Group, Inc. reports third quarter 2026 results
    PR·

    United Fire Group, Inc. reports third quarter 2026 results

    Third quarter net income of $1.34 per diluted shareand adjusted operating income of $1.34 per diluted share Third quarter 2026 highlights compared to third quarter 2025, unless otherwise noted:(1) Net income decreased $4.1 million to $35.1 million. Net investment income increased 13% to $29.3 million. Combined ratio increased 2.7 points to 94.6%, composed of an underlying loss ratio of 57.3%, catastrophe loss ratio of 2.4%, no prior year reserve development, and underwriting expense ratio of 34.9%. Underlying combined ratio increased 1.6 points to 92.2%. Net written premium(2) increased 13% to $371.4 million. Book value per share decreased $0.37 to $36.51 as of September 30, 2026, compared to D

    $UFCS
  • Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
    PR·

    Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

    Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic reactions, including anaphylaxis, if approvedCommercial preparations remain on track to support a potential U.S. launch of Anaphylm following FDA approvalEx-U.S. Anaphylm strategy progressing, with Health Canada submission expected in Q4 2026 and an EU filing planned for Q1 2027Company to host investor call on November 4, 2026, at 8:00 a.m.

    $AQST$ETON
  • Nurix Therapeutics Announces Sanofi’s Decision to Discontinue Development of STAT6 Degrader SAR448272
    PR·

    Nurix Therapeutics Announces Sanofi’s Decision to Discontinue Development of STAT6 Degrader SAR448272

    Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, today announced that Sanofi notified Nurix of its decision to discontinue the Phase 1 first-in-human clinical trial of SAR448272, an oral STAT6 degrader, and to terminate the SAR448272 program. As a result of Sanofi’s decision, Nurix does not anticipate receiving any of the future development, regulatory and commercial milestone payments or royalties for which it has been eligible under the collaboration with respect to the SAR448272 program. Nurix remains eligible to receive milestone payments and royalti

    $NRIX